Table 2 Clinical trials for HPV-associated pre-neoplastic lesions
From: Immunologic treatments for precancerous lesions and uterine cervical cancer
Vaccine | Antigen(s) | Phase | Lesions |
|---|---|---|---|
ADXS11-001: | HPV-16 E7 | II | CIN 2/3, VIN 3, VAIN 2 |
Lm secreting fusion/LLO-HPV-16 E7 protein (Lm-LLO-E7) | |||
Procervix: adenylate cyclase protein vector delivering HPV16 and HPV18 E7 antigens | HPV-16 and HPV-18 E7 | I/II | High-risk HPV infections before CIN appearance |
MVA E2: Recombinant Modified Vaccinia Ankara (MVA) encoding E2 from BPV | Bovine Papillomavirus E2 | I/II | CIN1-3 |
I/II | Male flat condyloma | ||
II | High-grade CIN | ||
TG4001/R3484: | HPV-16 E6/E7 | IIa | CIN2/3 |
Recombinant MVA expressing E6-E7of HPV-16, and IL-2 | IIb | ||
Peptides: HPV E7 (aa 12–20) plus E7 lipopetide (PADRE helper peptide, linker peptide, and E7 peptide: aa 86–93) & Montanide ISA-51 adjuvant | HPV-16 E7 | I | High-grade CIN and |
II | VIN | ||
II | VIN 3 | ||
HSIL | |||
HPV-16 E6/ E7 fusion protein plus ISCOMATRIX adjuvant | HPV-16 E6 and E7 | I | CIN 1–3, HPV-associated AIN in HIV-positive male |
PD-E7: Modified HPV-16 E7/Hib protein D fusion protein & AS02B adjuvant | HPV-16 E7 | I/II | CIN 1, CIN 3 |
SGN-00101: HPV-16 E7/M. bovis, Hsp65 fusion protein | HPV-16 E7 | I/II | Anal HSIL |
I/II | High-grade AIN | ||
II | ASCUS and LSIL, recurrent respiratory papillomatosis, high-grade CIN | ||
SGN-00101 in poly ICLC adjuvant | HPV-16 E7 | I | CIN 1-3 |
ZYC101: Recombinant HPV-16 E7 DNA Plasmid encapsulated in poly microparticles | HPV-16 E7 | I | High-grade AIN in males, CIN 2/3 |
ZYC101a: Recombinant HPV-16 and HPV 18 E6-E7 DNA Plasmid encapsulated in poly microparticles | HPV-16 and HPV-18 E6 and E7 | II/III | High grade CIN |
pNGVL4a-Sig/E7/Hsp70: DNA plasmid expressing mutated HPV-16 E7 fused to Sig and Hsp70 | HPV-16 E7 | I | CIN 2/3 |
pNGVL4a-CRT/E7: DNA plasmid expressing mutated HPV-16 E7 fused to calreticulin | HPV-16 E7 | I | CIN 2/3 |
VGX-3100: DNA plasmid expressing HPV-16 and HPV-18 E6 and E7 proteins | HPV-16 and HPV-18 E6 and E7 | I | CIN 2/3 (after surgery or fourth dose) |
II | CIN 2/3 | ||
TA-CIN/TA-HPV prime/boost | HPV-16 and HPV-18 E6 and E7 and HPV-16 L2 | II | CIN 2/3 |
TA-HPV/TA-CIN prime/boost | HPV-16 and HPV-18 E6 and E7 and HPV-16 L2 | II | CIN 2/3 |
pNGVL4a-Sig/E7 /Hsp70 and TA-HPV prime/boost plus TLR agonist imiquimod | HPV-16 and HPV-18 E6 and E7 | II | CIN 2/3 |